Propel Bio Management, LLC
Filing Date
Global Rank
#4,728
/ 8,623
▲ 819
· as of Mar 2026
Top Industry
Biotechnology
70.4%
3Y Alpha vs SPY
-0.6%
Period ended 4 months ago
Filed May 14, 2026 · 3mo
10 quarters · since Dec 2023
Clone Performance
Feb 2024–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Cloned portfolio
+45.1%
SPY
+50.3%
Annualised alpha
-1.7%
Max drawdown
−40.4%
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 100% of reported value on average across 10 quarters. Past performance does not predict future results.
Portfolio Concentration
38 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Top Position
19.5%
−1.3 pts
Top 5
41.9%
−20.1 pts
Top 10
58.4%
−25.5 pts
HHI
641
Diversified−404
Portfolio Trend
10 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 80.5% | $127,787,581 |
| Energy | 19.5% | $30,892,900 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| DCTH | Delcath Systems, Inc. | +541,189 | 979,698 | $9,091,597 | |
| ABEO | Abeona Therapeutics Inc. | +499,119 | 1,329,899 | $5,957,947 | |
| SABS | SAB Biotherapeutics, Inc. | +359,909 | 1,012,790 | $3,878,985 | |
| KLRS | Kalaris Therapeutics, Inc. | +253,718 | 295,771 | $1,706,598 | |
| ZVRA | Zevra Therapeutics, Inc. | +218,735 | 282,418 | $2,632,135 | |
| PHAT | Phathom Pharmaceuticals, Inc. | +100,354 | 841,272 | $9,346,531 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
6 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IVA | Inventiva S.A. | −275,322 | 724,678 | $4,021,962 | |
| CMPS | COMPASS Pathways plc | −119,729 | 742,049 | $4,103,530 | |
| VRDN | Viridian Therapeutics, Inc.\DE | −72,368 | 210,163 | $4,110,788 | |
| OCS | Oculis Holding AG | −50,616 | 122,223 | $3,249,909 | |
| CLDX | Celldex Therapeutics, Inc. | −22,936 | 131,364 | $4,166,866 | |
| KYTX | Kyverna Therapeutics, Inc. | −22,245 | 644,421 | $5,561,353 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
22 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CORT | Corcept Therapeutics Inc | 147,828 | $5,958,946 | |
| VOR | Vor Biopharma Inc. | 314,543 | $5,611,447 | |
| OBIO | Orchestra BioMed Holdings, Inc. | 896,701 | $3,810,979 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 380,420 | $3,541,710 | |
| OCUL | Ocular Therapeutix, Inc | 382,375 | $3,238,716 | |
| UPB | Upstream Bio, Inc. | 341,779 | $3,076,011 | |
| AQST | Aquestive Therapeutics, Inc. | 710,988 | $2,950,600 | |
| EYPT | EyePoint, Inc. | 215,825 | $2,781,984 | |
| TRVI | Trevi Therapeutics, Inc. | 223,802 | $2,669,957 | |
| IMUX | Immunic, Inc. | 2,344,779 | $2,602,704 | |
| CHRS | Coherus Oncology, Inc. | 1,420,550 | $2,400,729 | |
| OVID | Ovid Therapeutics Inc. | 921,457 | $2,045,634 | |
| PALI | Palisade Bio, Inc. | 1,115,000 | $1,951,250 | |
| QURE | uniQure N.V. | 104,772 | $1,713,022 | |
| NUVB | Nuvation Bio Inc. | 329,296 | $1,412,679 | |
| MAZE | Maze Therapeutics, Inc. | 43,798 | $1,307,370 | |
| EVMN | Evommune, Inc. | 55,664 | $1,279,715 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 85,791 | $1,255,122 | |
| ALDX | Aldeyra Therapeutics, Inc. | 730,606 | $1,234,724 | |
| ARTV | Artiva Biotherapeutics, Inc. | 146,369 | $942,616 | |
| CNTB | Connect Biopharma Holdings Ltd | 209,493 | $548,871 | |
| MSLE | Satellos Bioscience Inc. | 10,145 | $57,116 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
4 positions
38 tracked positions ·
$158,680,481 total
· filing declares
38 positions · $158,658,759
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PAGP |
Plains Gp Holdings LP
Energy
|
Held | 1,272,360 | $30,892,900 | 19.47% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
Held | 3,786,425 | $11,132,089 | 7.02% | |
| PHAT |
Phathom Pharmaceuticals, Inc.
Healthcare
|
Added | 841,272 | $9,346,531 | 5.89% | |
| DCTH |
Delcath Systems, Inc.
Healthcare
|
Added | 979,698 | $9,091,597 | 5.73% | |
| CORT |
Corcept Therapeutics Inc
Healthcare
|
NEW | 147,828 | $5,958,946 | 3.76% | |
| ABEO |
Abeona Therapeutics Inc.
Healthcare
|
Added | 1,329,899 | $5,957,947 | 3.75% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
NEW | 314,543 | $5,611,447 | 3.54% | |
| KYTX |
Kyverna Therapeutics, Inc.
Healthcare
|
Reduced | 644,421 | $5,561,353 | 3.50% | |
| MIST |
Milestone Pharmaceuticals Inc.
Healthcare
|
Held | 4,118,321 | $4,900,801 | 3.09% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 131,364 | $4,166,866 | 2.63% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Reduced | 210,163 | $4,110,788 | 2.59% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Reduced | 742,049 | $4,103,530 | 2.59% | |
| IVA |
Inventiva S.A.
Healthcare
|
Reduced | 724,678 | $4,021,962 | 2.53% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
Added | 1,012,790 | $3,878,985 | 2.44% | |
| OBIO |
Orchestra BioMed Holdings, Inc.
Healthcare
|
NEW | 896,701 | $3,810,979 | 2.40% | |
| FDMT |
4D Molecular Therapeutics, Inc.
Healthcare
|
NEW | 380,420 | $3,541,710 | 2.23% | |
| OCS |
Oculis Holding AG
Healthcare
|
Reduced | 122,223 | $3,249,909 | 2.05% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
NEW | 382,375 | $3,238,716 | 2.04% | |
| UPB |
Upstream Bio, Inc.
Healthcare
|
NEW | 341,779 | $3,076,011 | 1.94% | |
| AQST |
Aquestive Therapeutics, Inc.
Healthcare
|
NEW | 710,988 | $2,950,600 | 1.86% | |
| EYPT |
EyePoint, Inc.
Healthcare
|
NEW | 215,825 | $2,781,984 | 1.75% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
NEW | 223,802 | $2,669,957 | 1.68% | |
| ZVRA |
Zevra Therapeutics, Inc.
Healthcare
|
Added | 282,418 | $2,632,135 | 1.66% | |
| IMUX |
Immunic, Inc.
Healthcare
|
NEW | 2,344,779 | $2,602,704 | 1.64% | |
| CHRS |
Coherus Oncology, Inc.
Healthcare
|
NEW | 1,420,550 | $2,400,729 | 1.51% | |
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
NEW | 921,457 | $2,045,634 | 1.29% | |
| PALI |
Palisade Bio, Inc.
Healthcare
|
NEW | 1,115,000 | $1,951,250 | 1.23% | |
| QURE |
uniQure N.V.
Healthcare
|
NEW | 104,772 | $1,713,022 | 1.08% | |
| KLRS |
Kalaris Therapeutics, Inc.
Healthcare
|
Added | 295,771 | $1,706,598 | 1.08% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Held | 149,279 | $1,534,588 | 0.97% | |
| NUVB |
Nuvation Bio Inc.
Healthcare
|
NEW | 329,296 | $1,412,679 | 0.89% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
NEW | 43,798 | $1,307,370 | 0.82% | |
| EVMN |
Evommune, Inc.
Healthcare
|
NEW | 55,664 | $1,279,715 | 0.81% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
NEW | 85,791 | $1,255,122 | 0.79% | |
| ALDX |
Aldeyra Therapeutics, Inc.
Healthcare
|
NEW | 730,606 | $1,234,724 | 0.78% | |
| ARTV |
Artiva Biotherapeutics, Inc.
Healthcare
|
NEW | 146,369 | $942,616 | 0.59% | |
| CNTB |
Connect Biopharma Holdings Ltd
Healthcare
|
NEW | 209,493 | $548,871 | 0.35% | |
| MSLE |
Satellos Bioscience Inc.
Healthcare
|
NEW | 10,145 | $57,116 | 0.04% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.